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Summary Background: Previous studies have shown that the inflammatory response
to cigarette smoking differs between smokers who develop chronic obstructive
pulmonary disease (COPD) and those who do not and that the CD8þ T-lymphocytes
have been identified as a key player in this process. The aim of this study was to
investigate further the role of CD8þ cells and their subtypes in sputum cells.
Methods: Sputum induction was performed in 36 COPD patients, 25 smokers
without COPD and 10 non-smoking healthy controls. After stimulation of sputum
lymphocytes with phorbol-myristate-acetate, we used double immunocytochemical
methods to identify CD4þ , CD8þ cells and CD8þ INFg or IL4 cells (Tc1;Tc2).
Results: COPD patients had an increased number of CD8þ cells in sputum as
compared with smokers without COPD (P ¼ 0:0001) and control subjects (P ¼ 0:001).
CD8þ -IL4 cells were reduced both in COPD and in smokers without COPD compared to
controls (P ¼ 0:0001), while CD8þ -IFNg cells were significantly reduced only in COPD
(P ¼ 0:001) as compared with controls. A significant (P ¼ 0:02) relationship between
the CD8þ -IL4/CD8þ -IFNg ratio and FEV1 (% pred) was found only in COPD patients.
Conclusion: These findings suggest that an imbalance both in T-lymphocyte
subpopulation (CD4/CD8) and in CD8þ cell subsets (Tc1=Tc2) characterizes the
inflammatory responses of smokers with established COPD.
& 2003 Elsevier Ltd. All rights reserved.
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Introduction
It is widely accepted that abnormal inflammatory
responses to several noxious agents (smoking) play
an important role in the pathogenesis of chronic
obstructive pulmonary disease (COPD).1 Previous
studies have provided evidence for an inflammatory
process in the large airways of subjects with COPD
with symptoms of chronic bronchitis, consisting
predominantly of activated T-cells.2 In comparison
with smokers who did not develop airflow limita-
tion, patients with COPD have increased numbers
of CD8þ cells present in the small3 and large
airways.4,5 Although some reports have linked
CD8þ T-cells with the inflammation induced by
smoking itself,6,7 a significant correlation between
CD8þ numbers and FEV1 in COPD patients has been
reported.5 On the other hand, de Jong and
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colleagues have shown that CD8þ T-cells in
peripheral blood were increased in non-smoking
COPD patients, while the CD4/CD8þ ratio was
significantly correlated with lung function and
serum IgE.8 In addition, Majori and colleagues9
examined T-cell cytokine profile and reported a
Th1-like immune response of peripheral blood
CD4þ T-cells in subjects with COPD. Mattoli
et al.10 expanded these data to BAL samples of
COPD individuals with mainly chronic bronchitis
symptoms and showed that the CD8þ T-cell Th1Th2
phenotype of smokers with COPD is different from
the CD8þ T-cell clones of smokers without COPD.
The predominance of CD8þ T-cells in peripheral
blood, bronchial biopsies and in BAL seems to
display a clear difference between smokers with
COPD and without airflow limitation.3–5 However,
the precise function of the CD8þ T-cells in
pathogenesis of COPD has not been established. In
the current study, we assessed the cellular popula-
tions, and in particular, that of CD8þ T-cells and
their subtype in induced sputum in order to
investigate the role of CD8þ T-cells in the
pathogenesis of COPD. We compared a group of
current smokers who had already developed COPD
and a group of current smokers without COPD. We
recruited smokers with the same smoking history
but with and without COPD. In addition, measure-
ments were made in healthy non-smokers.
Material and methods
Subjects
Seventy-one males were studied: (a) 36 current
smokers with COPD; (b) 25 non-COPD current
smokers with a similar smoking history to the COPD
patients (Table 1); and (c) 10 healthy non-smokers.
The diagnosis of COPD was based on the European
consensus criteria including obstructive spirometry
(FEV1/VC ratio lower than 88% of that predicted for
men).11 All COPD patients had been free of an
acute exacerbation for at least 4 weeks preceding
the study and none had received antibiotics or
corticosteroids (oral and inhaled) or theophylline
over the same period. Neither smokers nor healthy
volunteers had a history of cardiopulmonary dis-
ease and all had normal lung function. All the
subjects were non-atopic (i.e. they had negative
skin tests for common allergen extracts) and had no
history of asthma or allergic rhinitis. The selection
of only males was not included in the design of this
study but was the consequence of the rarity of the
female COPD patients in Greece. We failed to
recruit a mixed population because, two screened
female COPD individuals refused to participate and
three other had concomitant disease. The Hospital
Ethical Committee approved the protocol and all
subjects gave their consent.
Spirometry and sputum induction
Spirometry with bronchodilation test was per-
formed with a computerized system (MasterLab;
2.12, Jaeger, Wuerzburg, Germany) according to
standardized guidelines.12 Subjects did not use
short or long acting bronchodilators during 12 h
prior to the measurements and did not smoke or
drink tea or coffee in the morning of the spirometry
and induced sputum. Spirometry and induced
sputum session always took place between 8.00–
11.00 a.m.
Sputum was induced via inhalation of a hyper-
tonic saline aerosol, generated by an ultrasonic
nebulizer (Ultraneb 2000; DeVilbiss, Somerset, PA,
USA) according to standard method13 and was
processed within 15min after termination of the
induction. The viscid portions of the expectorated
sample were separated from the sputum as
previously described.13
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Table 1 Demographics and spirometric values of the studied groups.
COPD Non-COPD smokers Healthy individuals
N 36 25 10
Sex M/F 36/0 26/0 10/0
Age years (x7SD) 6176.5 55.576.6 4979
Smoking habit (pack years (x7SD)) 50710 45710 F
FEV1/VC 56711 8476* 8775*
FEV1 (% pred.) 42.7718.9 9176.4* 10079**
DFEV1 (% baseline) (post-bronchodilation) 3.471.1 571.4 4.270.8
*Statistical significance between COPD and non-COPD smokers (Po0:01),
**Statistical significance between COPD and normal smokers (Po0:001).
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Sputum processing, total (TCC) and
differential cell counting (DCC)
The weight of the plugs was determined, and
dithiothreitol 0.1% (Sputolysin; Calbiochem, La
Jolla, CA, USA) twice the weight of the plugs was
added. The samples were agitated on a vortex
mixer in a wide-bore plastic test tube and placed in
a shaking water bath for 15min at 371C to ensure
complete homogenization. Subsequently, RPMI-
1640 plus 10% FCS (fetal calf serum) (GIBCO BRL,
Cheshire, UK) was added in a volume twice that of
the homogenized sample. The samples were then
filtered through a 48 mm nylon gauze (Thompson,
Ontario, Canada) and agitated on a vortex mixer
(suspension A). A total cell count (TCC) of the
filtered sample was performed and viability was
tested by means of the trypan blue exclusion
method. The suspension was then centrifuged at
400g for 5min and the pellet was resuspended with
500 ml RPMI-1640þ 10% FCS. The supernatant was
aspirated and stored in Eppendorf cups at 801C.
The samples were adjusted to a concentration of
0.35 106 cells/ml (suspension B). Cytospins were
made by putting 50 ml of this cell suspension in the
funnels of an aerospray cytocentrifuge (Wescor,
Claremont, Ont., Canada) at 300 rpm with low
deceleration for 5min. Two slides were stained
with May–Giemsa–Grunwald (MGG) stain for the
differential cell counts (DCCs). Five hundred non-
squamous cells in each coded MGG cytospin were
counted in a blinded fashion by two independent
investigators and averaged. Cell differential counts
were expressed as percentage of non-squamous
cells and as absolute number of cells per gram of
selected sputum sample. Absolute cell numbers
were calculated by multiplying the cell percentage
by the total (non-squamous) cell number in the
sputum, divided by the weight of the selected
sputum sample. The variability of the lymphocyte
DCCs per slide was examined and found no more
of 5%.
Immunocytochemical analysis and CD4þ ve
and CD8þ cells measurement
The immunocytochemical analysis and T-cell de-
termination were performed in sputum cytospins.
Briefly, sputum lymphocytes were stimulated by
incubating suspension B in 24-well plates at a
concentration of 2 103 cells/ml for 5 h, under
5% CO2, at 371C, in RPMI-1640 at 10% FCS in
the presence of phorbol 12-myristate 13-acetate
(PMA) 25 ng/ml, ionomycin 1 mmol and brebeldin A
10 mg/ml (Sigma-AldrichCorp. St. Louis, MO, USA).
Cytospins were made using cytocentrifugation of
50 ml of the stimulated suspension and were stored
at 801C for immunocytochemical analysis later.
Approximately 175,000 cells were cytospined on
each slide (3500 cells/ml 50 ml¼ 175,000 cells),
among which there was a sufficient number of
lymphocytes to stain.
After defrosting the slides, they were fixed in
acetone for 10min and rehydrated in Tris-Buffered
Saline (TBS). The double immunocytochemical
method was performed in two steps as previously
described.14 Briefly, the specimens were first
incubated for 30min with bovine serum to block
the unspecific binding and then were exposed to
the first primary antibody at a dilution of 1:50 for
30min at room temperature. After washing in TBS
three times they were exposed to the first
secondary antibody, rabbit anti-mouse immunoglo-
bulin fluorescein isothiocyanate (FITC)-conjugated
for 15min (ImmunotechMarseille, France) at a
dilution of 1:50. After washing in TBS three times
they were exposed to the second primary antibody
at a dilution of 1:50 for 30min at room tempera-
ture. After washing in TBS three times they were
exposed to the second secondary antibody, rabbit
anti-mouse immunoglobulin phycoerythrin-conju-
gated (IgG-PE) for 15min (Immunotech Marseille,
France) at a dilution of 1:50. After washing in TBS
three times the slides were mounted with 30%
glycerol in TBS. Two investigators examined the
slides under ultraviolet microscope and their
results were averaged. Three replicate measure-
ments were performed by each observer in 10
slides. Both intra- and inter-observer coefficient of
variation were o15%. The CD4/CD8 and CD8-INFg/
CD8-IL4þ ve cell ratio were calculated. For the
estimation of each ratio, 500 T-cells were counted,
with more than one cytospin stained if necessary,
because this number was sufficient to obtain a
mean value per subject that remained constant
after further increasing the number of cells
counted. Results were also expressed as percentage
of lymphocytes by dividing the number of lympho-
cytes stained per slide by total the number of
lymphocytes per slide. Negative controls were
obtained by the use of mouse-anti-mouse immu-
noglobulin to estimate the non-specific binding.
Positive controls were obtained by the use of T-
lymphoma cells cytospined on slides. Macrophages
were excluded from counting by morphology.
Measurement of CD4þ ve and CD8þ ve T-cells
The primary anti-CD4 mouse anti-human monoclo-
nal antibody (Caltag Burlingame, CA, USA) with
secondary rabbit anti-mouse IgG-FITC antibody
and the primary anti-CD8 mouse anti-human
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monoclonal antibody (Caltag Burlingame, CA, USA)
with secondary rabbit anti-mouse IgG-phycoery-
thrin-conjugated (IgG-PE) antibody were used. At
least 500 CD4þ ve and CD8þ cells were counted to
estimate CD4/CD8 ratio.
Measurement of CD8þ -IFNc producing and CD8þ -
IL4 producing T-cells
The primary anti-CD8 mouse anti-human monoclo-
nal antibody with secondary rabbit anti-mouse IgG-
FITC antibody and the primary anti-INFg mouse
anti-human monoclonal antibody (Caltag Burlin-
game, CA, USA) with secondary rabbit anti-mouse
IgG-phycoerythrin-conjugated (IgG-PE) antibody
were used. At least 500 CD8þ cells were counted
to estimate the number of CD8-INFgþ ve cells. The
same method was applied for staining CD8þ cells
with anti-IL4 antibody (Caltag Burlingame, CA, USA).
Statistics
Clinical characteristics are presented as mean7SD
and cell characteristics as median (range) unless
stated otherwise. Normality was detected using
the Kolmogorov–Smirnov test. Differences among
the three groups of subjects were tested using the
Kruskal–Wallis test for non-normal and ANOVA for
normal distributed variables. Once it had been
determined that differences existed between the
means, post hoc pairwise multiple comparisons
were made by Bonferroni test for parametric and
by Conover–Inman method15 for non-parametric
comparisons to determine which pair was statisti-
cally significantly different. Correlation between
cell parameters and physiological variables were
analyzed using Pearson’s correlation coefficient.
The statistical software StatsDirect (Camcode;
Cambridge, UK) was used for the entire analysis.
A P value of o0.05 was considered statistically
significant.
Results
Subjects
Demographic and spirometric data of the three
groups of subjects are shown in Table 1. The COPD
patients exhibited significantly lower values of FEV1
(% pred) and FEV1/VC (%) than non-COPD smokers,
though the smoking history was similar. There was
an age difference among the studied groups
although non-statisically significant. There were
no significant differences in FEV1/VC (%) and FEV1
(% pred) between non-COPD smokers and healthy
subjects. The postbroncodilation change in FEV1
(inhalation of 400mcg salbutamol) was similar in
the three groups (Table 1). The induced sputum
procedure was well tolerated by all subjects.
Cellular composition of induced sputum
The viability of the cells (% total) in induced sputum
did not differ between COPD, non-COPD smokers
and healthy controls: (median range) 84 (93–76), 86
(95–77) and 81 (88–72), respectively, (P ¼ 0:23).
More than 90% of the cells were non-squamous
cells. The TCC (gr1) was higher in patients with
COPD than in non-COPD smokers (P ¼ 0:001) and
controls (P ¼ 0:0001) (Table 2). The TCC was also
higher in non-COPD smokers than in healthy
individuals (P ¼ 0:05) (Table 2). The significant
differences in cellular parameters among three
groups are presented in Table 2. The most
significant differences between the three groups
were: neutrophil percentages were higher in COPD
than in the other two groups, whereas macrophage
percentages were lower in COPD than in the other
two groups (Table 2). Lymphocyte percentages
were lower in COPD than in the non-COPD smokers
and higher than in the healthy group (Table 2).
Lymphocyte and CD4þ , CD8þsubpopulations
The total number of CD8þ cells and their percen-
tage (% of lymphocytes) were significantly higher in
COPD patients compared with both non-COPD
smokers (P ¼ 0:0001) and healthy individuals
(P ¼ 0:0001) (Table 3). However, the comparison
of CD8þ cells (total numbers and percentage)
between non-COPD smokers and healthy group
showed no significant difference (Table 3). Signifi-
cantly lower percentages of CD4þ cells were found
in COPD patients compared with non-COPD smokers
(P ¼ 0:0001) and with healthy controls (P ¼ 0:0001)
(Table 3). In contrast, no significant difference in
CD4þ cells, percentages and total numbers, was
found between non-COPD smokers and healthy
controls. Patients with COPD had a significant
lower CD4/CD8 ratio compared with both non-
COPD smokers (P ¼ 0:001) and controls (P ¼ 0:002)
(Table 3). In contrast, the CD4/CD8 ratio did not
differ between non-COPD smokers and healthy
(P ¼ 0:8) (Table 3).
CD8þ subpopulations
The percentage of CD8-IFNg cells (Tc1) (% of CD8
þ )
in sputum was significantly (P ¼ 0:001) lower in
patients suffering from COPD than in smokers
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without COPD: 31 (11–80) vs. 46 (23–85), or healthy
controls 31 (11–80) vs. 54 (40–67) (P ¼ 0:001)
(Fig. 1). However, no significant difference was
found between smokers without COPD and healthy
controls (P ¼ 0:4) (Fig. 1). CD8-IL4 cells (Tc2) (% of
CD8þ ) in sputum did not differ between COPD and
non-COPD smokers: 3.5 (1–11) vs. 4 (1–15), (Fig. 2).
Patients with COPD had significant lower Tc2 cells
(% of CD8þ cells) than healthy controls: 3.5 (1–11)
vs. 23.6 (14–40), P ¼ 0:001 (Fig. 2). The same was
true concerning the comparison between smokers
without COPD and healthy group: 4 (1–15) vs. 23.6
(14–40), (Fig. 2).
CD8-IFNg cells to CD8-IL4 cells ratio (Tc1=Tc2)
was significantly lower in COPD than in non-COPD
smokers: 9 (1–27) vs. 13.6 (4–55), (Fig. 3). In
addition, smokers with COPD had a significantly
higher Tc1=Tc2 ratio than healthy controls: 9 (1–27)
vs. 2.6 (1–4), (Fig. 3). A significantly higher Tc1=Tc2
ratio was also found in smokers without COPD than
in healthy individuals: 13.6 (4–55) vs. 2.6 (1–4),
(Fig. 3). Only in COPD patients, there was a weak
but statistically significant (r ¼ 0:401; P ¼ 0:02)
correlation between the Tc1=Tc2 ratio and FEV1
(% pred) (Fig. 4).
Discussion
The main findings of the present study were that
COPD patients have increased numbers of CD8þ
ARTICLE IN PRESS
Table 3 T-lymphocyte subpopulations in sputum between COPD, non-COPD smokers and, healthy subjects
(median, ranges).
COPD smokers Non-COPD smokers Healthy P
(Group A, n ¼ 36) (Group B, n ¼ 25) (Group C, n ¼ 10)
CD8,  104 cells/g 40.9 (2–322) 13.9 (1–82) 16.9 (1.6–29) A vs. B: 0.005, B vs. C: NS,
A vs. C: 0.01
CD4,  104 cells/g 44 (2–483) 38.9 (4–415) 32.4 (5–94) A vs. B: NS, B vs. C: NS,
A vs. C: NS
CD8, % of lymphocytes 46 (24–58) 31 (4–50) 27.4 (24–41) A vs. B: 0.0001, B vs. C: NS,
A vs. C: 0.0001
CD4, % of lymphocytes 52 (40–71) 64 (3–86) 71 (42–77) A vs. B: 0.0001, B vs. C: NS,
A vs. C: 0.0001
CD4/CD8 ratio 1.1 (0.7–2.5) 2.01 (1–7.4) 2.44 (1.4–3.3) A vs. B: 0.0001, B vs. C: NS,
A vs. C: 0.008
Table 2 Cellular populations in sputum of COPD, non-COPD smokers and, healthy subjects (median, ranges).
COPD smokers Non-COPD smokers Healthy P
(Group A, n ¼ 36) (Group B, n ¼ 25) (Group C, n ¼ 10)
TCC,  107 cells/g 8.15 (1.1–18) 4.4 (0.7–8.0) 1.13 (0.2–2.0) A vs. B: 0.001, B vs. C: 0.05,
A vs. C: 0.0001
Neutrophils,  107 cells/g 6.35 (0.3–17.0) 1.73 (0.3–4.9) 0.41 (0.1–1.2) A vs. B: 0.0001, B vs. C: NS,
A vs. C: 0.0001
Macrophages,  107 cells/g 0.87 (0.09–3.4) 1.36 (0.05–4.0) 0.60 (0.09–1.5) A vs. B: NS, B vs. C: 0.008,
A vs. C: NS
Lymhocytes,  107 cells/g 0.13 (0.002-1.2) 0.11 (0.003–0.8) 0.07 (0.007–0.15) A vs. B: NS, B vs. C: NS,
A vs. C: 0.05
Eosinophils,  107 cells/g 0.09 (0–2.0) 0.08 (0–1.4) 0.006 (0–0.02) A vs. B: NS, B vs. C: NS,
A vs. C: NS
Neutrophils, % 80.7 (30–96) 54.7 (17–96) 37.9 (27–53) A vs. B: 0.0001, B vs. C: 0.02,
A vs. C: 0.0001
Macrophages, % 14.5 (10–70) 38.4 (20–80) 53.5 (39–68) A vs. B: 0.0001, B vs. C: 0.01,
A vs. C: 0.0001
Lymphocytes, % 1.6 (0.6–9.4) 3.1 (1.3–10) 1.1 (0.4–4) A vs. B: NS, B vs. C: 0. 002,
A vs. C: 0.05
Eosinophils, % 1.2 (0–18) 2.2 (0–38) 0.85 (0–2.2) A vs. B: NS, B vs. C: 0.01,
A vs. C: NS
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T-lymphocytes in sputum samples with a concurrent
imbalance between CD4þ and CD8þ (decreased
CD4þ/CD8þ ratio). In addition, our results showed
that there are significant differences in CD8þ
subtypes CD8þ -INFg (Tc1) and CD8þ -IL4 (Tc2) of
sputum cells between current smokers with estab-
lished COPD, smokers with an equivalent smoking
history but without COPD and non-smoking healthy
individuals. Although cigarette smoking has been
identified as the prime cause of COPD, it remains
unclear why only a small fraction of smokers
develop clinically relevant disease.16 It is therefore
of critical importance to study smokers who
develop COPD and to compare them with smokers
having a similar smoking history but without COPD.
The studied population was all male. Although
there is lack of data on gender differences in T-cell
immunity, this could be a limitation of the study as
our data cannot be precisely extrapolated to
women with COPD. Differences in the cellular
composition between smokers who develop COPD
and those without COPD have been reported in
bronchial biopsies2,4,17 and bronchoalveolar lavage
fluid.10 From these studies, it became apparent
that CD8þ lymphocytes could have a central role in
the inflammation of airways related to the patho-
genesis of the disease.18
In the present study, the method of induced
sputum was used to investigate T-lymphocytes in
COPD patients and to compare them with those in
smokers without COPD and in healthy, non-smoking
individuals. The method involves stimulation of
lymphocytes with PMA and ionomycin. Following
this procedure, immunocytochemical methods
were used to detect surface antigen and intracel-
lular cytokines. We demonstrate that sputum
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CD8þ cells and their immunological profile can be
studied by this method. Under these experimental
conditions of culturing and stimulating lymphocytes
with PMA the intracellular cytokine expression can
be affected. PMA is a potent stimulator of CD8þ
cells, which enhances their ability to express IL4 or
IFNg:19 It has been used to study human CD8þ cells
and their intracellular cytokine production in
asthma20 and in sarcoidosis.21 In the above reports,
PMA stimulation augmented the percentage of
IFNg- and IL4-producing T-suppressor/cytotoxic
lymphocytes, showing important effector differ-
ences in cytokine regulation not detectable other-
wise. We employed the same stimulation procedure
for the CD8þ subsets in all three groups of
subjects. Our findings although non-quantitative
demonstrated an important different intracellular
cytokine expression in smokers with established
COPD only after sufficient in vitro stimulation
with PMA.
Our results showed that the percentage of CD8þ
cell in COPD patients was significantly higher than
in smokers (P ¼ 0:0001) and in controls
(P ¼ 0:0001) (Table 3). About half of the lympho-
cytes in the sputum of COPD patients were CD8þ
cells. These results are in line with findings of
increased CD8þ in lung parenchyma, pulmonary
arteries17 and in the peripheral airways.3 It seems
that arteries, tissues, and airway lumen have a
similar CD8þ lymphocyte infiltration, suggesting a
CD8þ inflammation of the entire respiratory
system in smokers with COPD. There are several
ways in which the increased numbers of CD8þ cells
might be associated with inflammation in COPD.
The increased accumulation and activation could
be triggered by the smoking5 or by repeated virus
infections, a common cause of acute exacerba-
tions.22 On the other hand, CD8þ cells, because of
their potent cytotoxic abilities, may induce airway
and lung damage, especially when they are present
in excess and in activation.23 Even more, they may
contribute to inflammatory responses in lungs
through the release of cytokines although this
observation has been reported in animal studies.24
The findings of increased CD8þ cells in sputum,
beyond the confirmation of the findings of previous
studies of bronchial and lung biopsies, may be
clinically useful, since sputum induction is a
safe procedure and could be used to monitor
inflammatory changes in the lungs of COPD patients
over time.
In addition, the ratio of CD4þ to CD8þ cells was
found to be statistically significantly lower in COPD
patients than in smokers (P ¼ 0:0001) or controls
(P ¼ 0:008). The CD4þ/CD8þ ratio did not differ
between non-COPD smokers and controls. This
finding suggests that the ‘‘abnormal’’ inflammation
in COPD could be the result of an imbalance
between the CD8þ and the CD4þ T-lymphocytes,
which was observed only in those smokers who
developed COPD. When these observations are
linked with the study of Amadori et al.,25 who
reported a genetic control of the ratio between
CD4þ and CD8þ cells with a small (5%) percentage
of population having a CD4/CD8 ratio of lower
than 1, they also provide some evidence as to
why a minority of smoker will develop COPD. It is
possible that individuals with a genetically deter-
mined increase of the CD8þ population might be
more susceptible to further CD8þ cell abnormal-
ities.26 This genetically determined increase of
CD8þ cells might be enhanced by smoking5 or
repeated virus infections,22 inducing an abnormal
inflammatory response related to the pathogenesis
of COPD. This hypothesis is not new. It has
been suggested by O’ Shaughnessy and colleagues,5
who reported higher counts of CD8þ cells in
bronchial biopsies of smokers with COPD compared
to the smokers without COPD. Thus, the differences
in CD8þ cells between COPD and non-COPD
smokers found in this study could mean that
smoking is more likely to induce the develop-
ment of airflow limitation in individuals who have
a genetically determined tendency to a low CD4/
CD8 ratio.
In this study, using a immunocytochemical meth-
od after sufficient stimulation with PMA, we found
fewer sputum interferon-g producing CD8þ cells
(Tc1) in patients with COPD in comparison with
those in smokers and controls (Fig. 1). The mean
values of interleukin-4 expressing CD8þ cells were
similar in COPD and in smokers without COPD.
However, both were significantly lower than normal
(Fig. 2). It is obvious from Figs. 1 and 2 that a
significant proportion of CD8þ cells remain of
unknown cytokine profile (Tc0). The data of this
study are not sufficient to explore the cytokine
expression of the whole CD8þ subset. However, the
major difference found between smokers without
and with COPD is that seen in Tc1 cells (Figs. 1 and
2). This finding is also illustrated in Fig. 3, where
the Tc1=Tc2 ratio is presented. Figure 3 shows that
the Tc1=Tc2 ratio is low (2.6) in normal subjects,
increased in (13.6) in smokers without COPD and to
a lesser extent (9.5) in COPD patients. From these
results (Figs. 1–3), we could conclude that smoking
induces a dramatic drop in Tc2 in smokers both with
and without COPD.
However, smokers without COPD showed a
capacity of high Tc1 numbers, almost similar to
that found in controls (Fig. 1). We could submit that
the inflammation induced by smoking is different
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in ‘‘normal’’ smokers and in smokers with COPD at
the level of CD8þ subtypes. Thus, an imbalance
between Tc1=Tc2 may also be involved in the
pathogenesis of COPD. The CD8þ cells produce a
variety of cytokines, which in some instances
exceeds that of CD4Th subsets.27,28 The polariza-
tion of T-cell responses to either T1-type responses
(characterized by IFN-g production and related with
cell-mediated immunity) or T2-type responses
(characterized by IL4 and IL5 production and
associated mainly with humoral immunity) provides
a better basis for understanding how the T-cells
promote their interactions with other immune
cells. It is possible that the T-cell cytokine
imbalance seen in COPD promotes macrophage
activation. On activation, macrophages might en-
hance functions such as the generation of reactive
oxygen species and acute inflammation through the
secretion of short-lived non-specific inflammatory
mediators, such as eicosanoids and nitric oxide.29 In
addition, activated macrophages become more
efficient antigen-presenting cells; while CD4þ -
derived and CD8þ -derived IFN-g stimulate alveolar
macrophages to secrete cytokines, including IL12,
which feeds back into the cell lymphocyte line
promoting T-cells to differentiate into cytotoxic T-
lymphocyte differentiation.30
Both the CD4/CD8 and Tc1/Tc2 imbalance seen in
smokers with COPD may contribute to the abnormal
inflammation related to the development of COPD.
The observation in this study, that only in COPD
patients the FEV1 (% pred) was weakly but
statistically significantly related with the Tc1=Tc2
ratio (Fig. 4), provides further evidence for the
above hypothesis. The non-quantitative method
used in this study is an explanation of the quite
weak correlation observed between Tc1=Tc2 and
FEV1 in COPD patients. Although a correlation does
not always imply a cause–effect relationship, we
believe that the imbalance of CD8þ T-lymphocyte
subpopulation, seen primarily in COPD patients and
related to the expiratory airflow limitation (degree
of obstruction) (FEV1), provides sufficient evidence
for further investigation of its role in the pathogen-
esis of COPD.
In conclusion, our findings demonstrated a
different inflammatory response to cigarette smok-
ing at the level of T-cell lymphocytes between
COPD and current smoker. A predominance of CD8þ
cells in sputum and the consequent imbalance of
the CD4/CD8 ratio was shown in smokers with
COPD. We report an imbalance of sputum CD8þ
subsets, such as the CD8þ -INFg/CD8þ -IL4 ratio
that may provide new insight into the pathogenesis
of COPD. However, the precise role of these cells
(Tc1;Tc2) remains to be investigated.
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